Conclusions
PD, hyperphosphatemia, diarrhea
HYPERPHOSPHATEMIA
For patients with hyperphosphatemia undergoing PD, tenapanor resulted in clinically meaningful decreases in serum P levels and target serum phosphorus level achievement per current guidelines at week 8 by approximately half of the patients with tenapanor alone. Treatment with tenapanor for 16 weeks was considered safe and tolerable for PD patients, with all cases of diarrhea being mild or moderate and occurring at the beginning of treatment. In conclusion, tenapanor is a first-in-class drug with a different mechanism of action from existing phosphate binder therapies and could be a new treatment option for PD patients.